Lifestyle Asset Management Inc. Takes Position in Doximity, Inc. (NASDAQ:DOCS)

Lifestyle Asset Management Inc. purchased a new stake in shares of Doximity, Inc. (NASDAQ:DOCS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,665 shares of the company’s stock, valued at approximately $356,000.

Other hedge funds have also added to or reduced their stakes in the company. FMR LLC boosted its stake in Doximity by 30.5% in the third quarter. FMR LLC now owns 6,837,733 shares of the company’s stock valued at $297,920,000 after acquiring an additional 1,598,602 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Doximity in the third quarter worth about $29,453,000. Los Angeles Capital Management LLC boosted its holdings in shares of Doximity by 6,242.6% in the third quarter. Los Angeles Capital Management LLC now owns 650,874 shares of the company’s stock valued at $28,359,000 after buying an additional 640,612 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Doximity in the 3rd quarter valued at approximately $24,691,000. Finally, Geode Capital Management LLC lifted its position in shares of Doximity by 19.8% in the third quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock worth $124,503,000 after purchasing an additional 472,565 shares in the last quarter. Institutional investors own 87.19% of the company’s stock.

Doximity Trading Down 0.6 %

NASDAQ DOCS opened at $55.69 on Friday. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $61.75. The firm has a market capitalization of $10.40 billion, a price-to-earnings ratio of 64.02, a P/E/G ratio of 4.39 and a beta of 1.38. The firm’s 50 day simple moving average is $53.66 and its 200 day simple moving average is $43.22.

Doximity (NASDAQ:DOCS) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02). The business had revenue of $136.83 million for the quarter, compared to analyst estimates of $127.05 million. Doximity had a return on equity of 19.79% and a net margin of 33.69%. During the same period last year, the firm posted $0.18 EPS. On average, equities research analysts forecast that Doximity, Inc. will post 0.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Evercore ISI lifted their price target on shares of Doximity from $34.00 to $45.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Canaccord Genuity Group lowered Doximity from a “buy” rating to a “hold” rating and boosted their price target for the stock from $40.00 to $60.00 in a research report on Wednesday, November 13th. Barclays raised their target price on shares of Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. The Goldman Sachs Group began coverage on shares of Doximity in a research report on Friday, November 15th. They issued a “neutral” rating and a $58.00 price objective on the stock. Finally, Mizuho started coverage on Doximity in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $55.00 target price on the stock. Thirteen equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $53.12.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.